SprycelTreatment for Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib
PRINCETON, N.J., June 02, 2006 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee voted in favor of recommending accelerated approval of dasatinib, the company's investigational compound, for the treatment of adults in all phases of chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate). Phases of CML include chronic, accelerated, lymphoid blast and myeloid blast. The Committee also recommended full approval of dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to imatinib. While the FDA is not bound by the committee's recommendations, they generally follow the advice of the panel.
When Bristol-Myers Squibb submitted its new drug application (NDA) for dasatinib, the FDA granted a priority review -- a status reserved for products that address unmet medical needs. Based on the priority review, the FDA's action date for the NDA is June 28, 2006.
"Bristol-Myers Squibb is dedicated to conducting research and to developing therapies designed to aid in the fight against serious diseases with unmet medical needs, such as leukemias and other malignancies," said Elliott Sigal, chief scientific officer, and president, Pharmaceutical Research Institute, Bristol-Myers Squibb. "We are committed to working with the FDA to support the potential approval of dasatinib."
Dasatinib was discovered and is being developed by scientists within Bristol-Myers Squibb.
The FDA Oncologic Drugs Advisory Committee based their recommendation on review of data from the dasatinib clinical development program. Data included safety and efficacy results from five international, multi-center Phase II trials, together with other supportive data. Phase II trials analyzed data from all phases of CML or Ph+ ALL in patients resistant or intolerant to prior therapy.
About CML and Ph+ ALL
CML is a cancer of the blood and bone marrow that usually occurs during or after middle age and rarely occurs in children. The incidence of resistance increases with the number of years on treatment and severity of disease.
Ph+ ALL is a rapidly progressive cancer of the blood and bone marrow that usually occurs in adults. Patients with advanced Ph+ ALL generally develop resistance more rapidly than CML patients, including those in blast phase (an average of 2 months versus 10 months, respectively).
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Source: Bristol-Myers Squibb
Posted: June 2006
- FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase - June 21, 2013
- FDA approves additional medical indication for Sprycel - October 28, 2010
- FDA Grants Full Approval for Sprycel (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec - May 26, 2009
- FDA Approves New Sprycel (Dasatinib) Product Labeling for Patients with Chronic-Phase CML - November 9, 2007
- Sprycel Bristol-Myers Squibb Company - Treatment for Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) - June 28, 2006
- FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib - March 7, 2006
- Bristol-Myers Squibb Submits New Drug Application for Dasatinib - December 28, 2005